Treatment outcome for patients with primary NSCLC and synchronous solitary metastasis
Qinghua Xu(Anhui Academy of Medical Sciences), Caicun Zhou(Tongji University), Jian Xu(University of California, Los Angeles), Shuyan Meng(Tongji University), Gerald Schmid‐Bindert(Heidelberg University), Yang Wang(University of Science and Technology of China), Songwen Zhou(Tongji University), H. Liu(Tongji University)
Cited by 35
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
|The Lancet Oncology|2015|1.6k
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
|The Lancet Oncology|2015|980
HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
|Gastric Cancer|2014|615
Circulating MicroRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis
|Molecular Carcinogenesis|2010|558